The utility of an in vitro system to search for molecular targets and markers of developmental toxicity was explored, using microarrays to detect genes susceptible to deregulation by the teratogen valproic acid (VPA) in the pluripotent mouse embryonal carcinoma cell line P19. Total RNA extracted from P19 cells cultured in the absence or presence of 1, 2.5, or 10mM VPA for 1.5, 6, or 24 h was subjected to replicated microarray analysis, using CodeLink UniSet I Mouse 20K Expression Bioarrays. A moderated F-test revealed a significant VPA response for 2972 (p < 10 23 ) array probes (19.4% of the filtered gene list), 421 of which were significant across all time points. In a core subset of VPA target genes whose expression was downregulated (68 genes) or upregulated (125 genes) with high probability (p < 10 27 ) after both 1.5 and 6 h of VPA exposure, there was a significant enrichment of the biological process Gene Ontology term transcriptional regulation among downregulated genes, and apoptosis among upregulated, and two of the downregulated genes (Folr1 and Gtf2i) have a knockout phenotype comprising exencephaly, the major malformation induced by VPA in mice. The VPA-induced gene expression response in P19 cells indicated that~30% of the~200 genes known from genetic mouse models to be associated with neural tube defects may be potential VPA targets, suggestive of a combined deregulation of multiple genes as a possible mechanism of VPA teratogenicity. Gene expression responses related to other known effects of VPA (histone deacetylase inhibition, G 1 -phase cell cycle arrest, induction of apoptosis) were also identified. This study indicates that toxicogenomic responses to a teratogenic compound in vitro may correlate with known in vitro and in vivo effects, and that shorttime (£6 h) exposures in such an in vitro system could provide a useful component in mechanistic studies and screening tests in developmental toxicology.
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The risk of adverse effects on the developing human is one of the most important safety issues that must be assessed prior to the launching of a pharmaceutical drug onto the market. Unlike general toxicity, which can be characterized during clinical trials as well as in animal experiments, developmental toxicity is not likely to be recognized in the human until affected pregnancies become significant in the birth registry. The preclinical information obtained in the comprehensive whole-animal studies in mammals, which are mandated by current regulatory testing guidelines (Christian et al., 2006) , is therefore fundamental not only in hazard identification and the prediction of human risk, but also has a lingering impact on drug classification, labeling, and clinical use. Although funding sources (including the agency funding the present research) and regulatory authorities increasingly encourage moving away from animal use in research and risk assessment, the prospect of being able to ultimately replace the resource-intensive animal testing programs with developmental toxicity testing in vitro (Spielmann, 2005; Spielmann et al., 2006) is limited by several factors, one of which is the currently inadequate knowledge about mechanisms of teratogenesis.
An appealing approach toward revealing molecular targets, pathways, and markers of toxicity is to study the short-term effects of known toxicants on the transcriptome of relevant model systems and to correlate the detected gene expression changes with traditional toxicological endpoints. Even if there is not always a strict correlation between the levels of a given transcript and its corresponding active protein, the current technologies for assessing relative mRNA expression levels (e.g., DNA microarrays and quantitative real-time reverse transcription PCR) have several advantages in terms of throughput, cost, sensitivity, and reproducibility compared with the corresponding methods for proteins. The mechanistic information derived from such toxicogenomics studies would not only be valuable in the validation of in vitro methods, but could also assist in the evaluation of the in vivo developmental toxicity tests. Moreover, genes whose expression responds to toxic exposure in vitro provide potential molecular markers that could be effectively applied as robust quantitative endpoints in high-throughput screens designed to guide early decision-making amongst closely related chemical compounds. This would potentially decrease the number of candidate drugs showing adverse effects in the full-scale developmental toxicity tests, and might also contribute to an overall reduction in the use of laboratory animals in drug development. In a pilot microarray study in mouse embryos and mouse embryonal carcinoma cells (P19), we found that exposure to the wellknown teratogen valproic acid (VPA), a potent inducer of neural tube defects (NTDs) in vertebrate embryos , results in altered mRNA expression levels of multiple genes (Kultima et al., 2004) . That several of these genes respond similarly in the in vitro and in vivo model, and belong to functional categories relevant to developmental processes affected in teratogenesis, implied the intriguing possibility of being able to use an in vitro system to find marker genes whose expression responses in vitro could be predictive of potential developmental toxicity in vivo.
This study explores the utility of a simple in vitro system in the mechanistic characterization of a developmental toxicant (VPA), using microarrays. In early embryos, many cells are likely to show some degree of pluripotency, which possibly involves the active expression or absence of irreversible silencing of a larger fraction of the genome compared with more differentiated cells later in life. An embryo-derived pluripotent stem cell (Boiani and Scholer, 2005) line (P19) was therefore employed as a potentially relevant model cell type. When cultured in a monolayer system these cells are unlikely to become involved in the multitude of complex interactions and morphogenetic activities typical of those in a developing embryo. Genes whose expression may inherently be susceptible to deregulation by toxic exposure could thus readily be uncovered in such a simple cell-based system. This might apply especially to genes targeted by the primary mechanism of action, but also to those regulated downstream of primary targets.
Genes whose expression is influenced as a low-dose and short-term effect of exposure to a toxicant are less likely to be deregulated secondary to cytotoxicity or other adverse cellular effects. Such genes therefore emerge as particularly attractive candidates for further pursuit as potential mechanism-based markers of toxicity. Based on these considerations, the current study was undertaken to identify genes whose expression may inherently be susceptible to deregulation by VPA during early embryogenesis, exploiting P19 cells as a model system. In order to facilitate the identification of such genes using microarrays, their persistent or increased gene expression responses at higher exposures was utilized. The study thus takes advantage of an attractive feature of toxicology in vitro: the opportunity to subject cultured cells to higher exposures than would be achievable in the in vivo situation. In the case of VPA, the pregnant dam is heavily sedated at exposures (ip injection of 600 mg/kg bodyweight on gestational day 8 in the Naval Medical Research Institute (NMRI) mouse strain) inducing NTD (exencephaly) in~50-60% of the embryos in a litter (Kultima et al., 2004; Nau and Löscher, 1986) . Even if VPA is known to accumulate in the neuroepithelium of the mouse embryo (Dencker et al., 1990 ), it appears unlikely that embryonic cells in vivo would be exposed to levels of VPA exceeding 6-7mM (H. Nau, personal communication) for other than a highly transient period of time after maternal dosing. This might be reflected in the moderate fold changes in gene expression previously detected by microarrays in whole embryos 6 h after maternal VPA exposure, and which for several genes were similar to those detected in P19 cells exposed to 1mM VPA for 24 h (Kultima et al., 2004) . For cells cultured in vitro, a higher exposure (i.e., a greater area under the time versus concentration curve) can be attained through the use of higher concentrations and/or longer exposure times.
In order to evaluate the potential relevance of the in vitro system, this study investigates the ability of VPA to deregulate genes known from the published literature to be involved in processes disturbed by VPA in teratogenesis. We present data showing that a substantial number of the genes deduced from genetic mouse models to be critically important in neural tube development and closure (Copp et al., 2003; Harris and Juriloff, 2007) may be VPA targets. This study also examines the toxicogenomic responses of genes attributed to one of VPA's recognized modes of action, histone deacetylase (HDAC) inhibition (Glaser et al., 2003; Marks et al., 2003; Zupkovitz et al., 2006) , a primary mechanism by which VPA is thought to deregulate gene expression (Göttlicher et al., 2001; Phiel et al., 2001; Reid et al., 2005) . We report VPA-induced deregulation of several genes known to be targets downstream of other HDAC inhibitors (Glaser et al., 2003; Marks et al., 2003) , and of putative Hdac1 downstream target genes derived from the reanalysis of a publically available microarray data set generated in a study of embryonic stem (ES) cells obtained from Hdac1 À/À and wild-type mice (Zupkovitz et al., 2006) . The results are discussed in relation to the potential role of gene deregulation in VPA teratogenesis.
MATERIALS AND METHODS
Cells. P19 mouse embryonal carcinoma cells (ATCC CRL-1825; American Type Culture Collection, Manassas, VA) were cultured at 37°C and 5% CO 2 in Dulbecco's Modified Eagle's Medium (Swedish National Veterinary Institute, Uppsala, Sweden), supplemented with 10% fetal bovine serum (Swedish National Veterinary Institute), 2mM L-glutamine, 100 U/ml penicillin, and 100 lg/ml streptavidin. Cells were split 1:10 every second to third day.
Cell viability. P19 cells were seeded at a density of 3 3 10 5 cells per 10-cm plate in 10 ml of medium and cultured overnight before being exposed to 0, 0.5, 1, 2.5, 5, 10, or 25mM VPA through the addition of 10 ll of 10003 stock VALPROIC ACID-INDUCED GENE DEREGULATION solution of sodium valproate (Sigma-Aldrich, St Louis, MO) dissolved in water. After 24 h of exposure, the culture medium was removed and the plates washed once with phosphate-buffered saline (PBS). The attached cells were then trypsinated, resuspended in medium, and pooled with the detached cells recovered from the culture medium and PBS used for washing. The effect of VPA on cell viability was determined using the trypan blue exclusion assay (Mishell and Shiigi, 1980) . Viable (trypan blue-excluding) and dead (trypan blue-stained) cells were counted using a Bürker chamber. The experiment, which used duplicate plates for VPA-exposed cells and triplicate plates for the controls, was repeated four times. Extra plates were done in order to determine the number of cells at the start of exposure. All cell counts were logtransformed prior to statistical analysis. Because the whole experiment was repeated four times, a linear model including the factor for experimental block was fitted for each of the endpoints: total cell count, viability, and number of dead cells. For pair-wise comparisons between exposed and control level we used Dunnett's test (Dunnett, 1955) .
Apoptosis detection. The effect of VPA on caspase-3 cleavage was determined with Western blot. P19 cells were exposed to 0, 1, 2.5, 5, or 10mM VPA for 24 h, as described above. Cells were washed twice with ice-cold PBS, lysed with modified RIPA buffer (1% NP-40, 0.25% Na-deoxycholate, 1mM EDTA, and Tris, pH 7.4), shaken for 30 min at 4°C, and centrifuged at 12,000 3 g for 20 min. The supernatant was recovered, and the protein concentration determined using Bio-Rad BCA protein assay (Bio-Rad, Hercules, CA). Protein samples (10 lg) were mixed with sample loading buffer (6.25mM Tris, pH 6.8, 2.5% glycerol, 0.2% SDS, 0.04% bromophenol blue, and 0.75M b-mercaptoethanol), boiled for 4 min, and subjected to sodium dodecyl sulfatepolyacrlamide gel electrophoresis in precast 15% homogenous polyacrylamide gels (Bio-Rad), followed by electroblotting to polyvinylidene fluoride membranes. BenchMark Pre-Stained Protein Ladder (Invitrogen, Carlsbad, CA) was used as molecular weight markers. The membranes were blocked with 4% nonfat dry milk in Tris-buffered saline, 0.1% Tween-20 (TBS-T) for 1 h at room temperature (RT). Incubation with primary antibody against cleaved caspase-3 (Cell Signaling Technology, Inc., Danvers, MA) (1:3000) was performed overnight at 4°C, after which they were washed three times with TBS-T. Secondary antibody incubation with horseradish peroxide-conjugated goat anti-rabbit IgG (Millipore Corporation, Billerica, MA) (1:7000) was performed for 1 h at RT, after which the blots were washed three times with TBS-T. Bound secondary antibody was detected using ECL Advance Western Blotting Detection Kit (GE Healthcare, Piscataway, NJ) reagent according to the manufacturer's instructions, and visualized by exposure to Fuji Super RX X-ray film. To confirm equal protein load, the membrane was then incubated with stripping buffer (100mM b-mercaptoethanol, 2% SDS, 62.5mM Tris-HCl, pH 6.7), blocked, incubated with primary antibody against b-actin (Cell Signaling #4970) (1:1000) overnight at 4°C, washed, incubated with secondary antibody, and detected as described above.
RNA isolation. Cells, exposed as described below, were quickly washed twice with PBS and lysed with 3 ml of Trizol reagent (Invitrogen, Carlsbad, CA) for 5 min at RT. Genomic DNA was sheared by drawing the lysate several times through a pipette until the extract appeared nonviscous. The lysate was subsequently stored at À70°C until further use.
Freeze-stored TRIzol lysates were thawed and chloroform-extracted. Following centrifugation, the upper aqueous phase was mixed with isopropyl alcohol and centrifuged to precipitate RNA. Total RNA was washed once with 75% ethanol, and dissolved in RNase-free water, and stored at À70°C. RNA concentration was determined in a NanoDrop ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington, DE) , and the quality and integrity checked in an Agilent 2100 Bioanalyzer, using the RNA 6000 LabChip (Agilent Technologies, Santa Clara, CA). Only high quality RNA, with no signs of degradation, was used for further experiments.
Experimental design of microarray gene expression analysis. All the cells originating from one plate of P19 cells seeded at a density of 2 3 10 5 cells per 6-cm plate, cultured overnight, and further cultured for 1.5, 6, or 24 h in the absence or presence of 1, 2.5, or 10mM VPA, correspond to one sample.
A design utilizing fewer replicate samples for the higher concentrations than for the low concentration (and control) was chosen in order to minimize the number of arrays while obtaining sufficient data points for the control and the exposure where smaller effects might be anticipated. Therefore, labeled cRNA (see below) from three control samples and three 1mM, two 2.5mM and one 10mM VPA-exposed samples from each of the three time points were hybridized to 27 CodeLink UniSet I Mouse 20K Expression Bioarrays (GE Healthcare, Piscataway, NJ, now Applied Microarrays, Tempe, AZ), a singledye microarray labeling system. In addition, for the 1.5-h time point an extra technical replicate was added for each of the control and the 2.5 and 10mM VPA exposures, resulting in a total of 30 array hybridizations.
cRNA synthesis and microarray hybridizations. For each microarray, 1 lg total RNA was converted to double-stranded cDNA and subsequently to cRNA, using CodeLink Expression Assay Reagent Kit (GE Healthcare), and hybridized to arrays according to the manufacturer's instructions. Briefly, total RNA was spiked with an equal amount of bacterial control mRNA prior to single-stranded cDNA synthesis with T7 oligo(dT) primer, 5mM dNTP mix and reverse transcriptase at 42°C. The second strand was subsequently synthesized using 5mM dNTP mix and DNA polymerase mix at 17°C in a refrigerated chamber. Double-stranded cDNA was purified using QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) and concentrated in a Speed Vac Plus (Savant, Ramsey, MN). cRNA was synthesized by in vitro transcription (IVT) where biotin-11-UTP (PerkinElmer, Boston, MA) was incorporated into the cRNA. IVT reaction was performed at 37°C for 15 h, and cRNA was then recovered by RNeasy Mini Kit (Qiagen). Assessment of concentration and quality was performed using NanoDrop instrument and Agilent 2100 Bioanalyzer. The biotin-11-UTP-labeled cRNA was fragmented through incubation with fragmentation buffer for 20 min at 94°C, and 10 lg of fragmented cRNA was hybridized to each array for 18 h at 37°C at 300 rpm on a shaker. Excessive cRNA was washed off in 0.753 TNT buffer for exactly 1 h at 46°C, after which hybridized cRNA was stained with Cy5-Streptavidin (Amersham Biosciences, Uppsala, Sweden) at ambient temperature for 30 min. After washing four to six times for 5 min in 13 TNT buffer and one to two times for 30 s in 0.13 SSC/Tween-20, the slides were dried by centrifugation at 640 3 g.
Microarray scanning. Scanning of the arrays was carried out on a GenePix 4000B scanner (Axon Instruments, Foster City, CA) with a pixel size resolution of 10 lm. Scanned image files were quantified using CodeLink Expression Analysis Software (GE Healthcare) to obtain mean intensity and median background-subtracted values of each spot, as recommended by the manufacturer. Only spots classified as ''Discovery,'' ''Other,'' or ''Positive'' by the CodeLink system were included for downstream analysis. All these spots were further filtered on the basis of different quality criteria as given by the CodeLink software. Several different types of flags exist, but essentially all spots not flagged as ''GOOD'' or ''LOW'' were removed. Additionally, only spots for which there were at least 50% ''GOOD'' spots totally for each time point studied were included. This procedure ensures that spots that can be considered as having ''LOW'' intensity and therefore to be more variable, irrespective of treatment effects, are removed. After filtering, a data set of 15,308 array elements (from the original 20,289) was used for downstream analysis.
Microarray data analysis. To normalize data, to calculate the expression change and the statistical significance of change (p values and F and t-statistics), and to address the problem with multiple testing, adjusting according to (Benjamini and Hochberg, 1995) , we used the statistical R software (Team, 2008) and the ''affy'' , ''affyPLM'' (Bolstad, 2007) , ''Impute'' (Gentleman et al., 2004) and ''Limma'' (Smyth, 2005) BioConductor (Gentleman et al., 2004) packages. For principal component analysis (PCA) (Wold, 1966) , the MATLAB programming environment, version 7.3.0.267 (The MathWorks, Inc., Natick, MA), was used with default settings to calculate the principal components. For Gene Ontology (GO) analysis, the freely available LCB Data Warehouse (Ameur et al., 2006) was used. The CodeLink data has been loaded into ArrayExpress (http://www.ebi.ac.uk/), accession E-MEXP-981.
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To remove systematic sources of variation for the CodeLink Bioarrays, CyclicLoess was used as described by Wu et al. (2005) . In brief, CyclicLoess uses the intensity and fold change (MA plot) in a pair of microarrays and then removes the difference by centering the loess line to zero. This procedure was carried out in a pair-wise manner for all the arrays in our data set and iterated until intensity-dependent differences were removed from all arrays. Because background subtraction was used, some spot intensity resulted in negative values. Spot values with a large negative value were excluded (< 20 spots in total) and thereafter, for each microarray, a small positive value was added to all remaining values such that all values ended up positive. Finally, spots that had been filtered as ''BAD,'' named ''M'' values in the CodeLink software, were permuted using the k-nearest neighbor averaging function in BioConductor package Impute, with default settings. This was done because the CyclicLoess function cannot handle missing values. These permuted and normalized values were subsequently removed after normalization. After addition of equal amounts of control RNA in all hybridizations and proper normalization, there should be no difference in the relative expression of control spots between arrays. For the window (also known as ''span'') of the CyclicLoess function, we used a value of 0.1 instead of the default 0.4. This was done because the average difference between arrays in the expression of ''POSITIVE'' control spots was approximately zero on a log 2 scale, compared with a value deviating from zero when using the default of 0.4 (data not shown).
To find genes whose expression was altered by VPA, we used a linear model in which the expression in cells exposed to 1 and 2.5mM VPA was compared with the expression in the controls of each corresponding time point. This means that for each of the three time points studied, three biological control replicates were compared with five exposure replicates (three 1mM and two 2.5mM VPA). The highest dose (10mM) was not included in the statistical analysis. To promote the selection of genes whose expression was altered at more than one time point, the statistical analysis was done using a moderated F-test (Smyth, 2004) .
In an additional analysis, the overall VPA response at each time point was estimated using the average log 2 fold change across all three concentrations (M av ), calculated as the average log 2 fold change of the VPA response (vs. controls) across all arrays used to measure samples from VPA-exposed cells (i.e., three for 1mM, two for 2.5mM, and one for 10mM, with the exceptions for 1.5 h noted above). Genes with a VPA response were defined as those having jM av j > 0.75 at any time point, or a consistent down (M av < À0.5) or up (M av > 0.5) response across two consecutive time points.
For GO analyses, clones were filtered for redundancy in order to include only unique gene identifiers. Only the biological process ontology was considered, disregarding the molecular function and cellular component annotations. To find over-represented GO terms, a one-sided Fisher's Exact test (p < 0.05) was used, where differentially expressed down-and upregulated genes were compared with a background distribution of GO terms. As background, we used the 15,308 filtered clones (14,693 unique genes).
To perform reanalysis of microarray data from Zupkovitz et al. (2006) , raw data was downloaded from ArrayExpress and normalized using the robust multiarray average (RMA) (Irizarry et al., 2003) method. To search for the differentially expressed genes between ES cells derived from Hdac1 À/À and wild-type mice, the moderated t-test was then applied (Smyth, 2004) . This generated a list of 168 putative Hdac1 target genes, 114 of which were upregulated (2.8% of 4511 probes called present in all Affymetrix arrays of Hdac1 À/À ES cells) and 54 downregulated (1.4% of 4406 probes called present in all Affymetrix arrays of wild-type ES cells) with a fold change > 2 (logarithm of odds (lod) score > 0; see Lönnstedt and Speed (2002) for a discussion about lod score) in the absence of functional Hdac1.
Quantitative real-time reverse transcription polymerase chain reaction. To confirm the identity and VPA responsiveness of selected genes identified in the microarray analysis as being down-or upregulated by VPA (Supplemental Table 1 ), quantitative real-time reverse transcription polymerase chain reaction (qPCR) was used. Primers for selected genes (Supplemental Table 1 ) were designed using Universal ProbeLibrary Assay Design Center (https://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp) and synthesized by DNA Technology A/S (Aarhus, Denmark). The primer pairs were designed using exon-exon spanning, melting temperatures around 60°C, and 100-to 150-bp amplicons. As an internal reference we used the geometric mean of the common reference genes Tbp, Actb, and Arbp whose expression, according to the microarray data, are unlikely to be altered by VPA in P19 cells.
For qPCR, the same time points (1.5, 6, and 24 h) as in the microarray analysis were investigated, but instead of replicating the same concentrations we chose to study an extended dose range (0.25-10mM) including an intermediate concentration (5mM). For each time point, three biological replicates were made for the controls, and a single replicate each for 0.5, 1, 2.5, 5, or 10mM VPA. Briefly, 1 lg total RNA was reverse transcribed in a final volume of 50 ll using Multiscribe Reverse Transcriptase with random hexamers according to manufacturer instructions (Applied Biosystems, Foster City, CA). cDNA targets at a 100-fold final dilution were amplified in triplicate wells, using SYBR Green I PCR Mastermix (Eurogentec, Ougree, Belgium) containing 10nM fluorescein, in the presence of 0.3lM forward and reverse primers in a final reaction volume of 25 ll, using an iCyclerIQ (Bio-Rad) with the following thermal profile: 95°C for 7 min followed by 40 cycles of 20 s at 94°C, and 1 min at 60°C. To assess the specificity of PCR products, melting curves were run subsequently to amplification. The amplification efficiency was calculated by linear regression of the raw data from the amplification plots using the program LinReg (Ramakers et al., 2003) and the average efficiency of all individual reactions for each qPCR plate was used.
As a measurement of the relative abundance of target gene transcript in each sample, a mean normalized expression (MNE) was calculated (excluding outlier wells) based on the ratio between target and reference gene, as described by Muller et al. (2002) . As proposed by Vandesompele et al. (2002) , we calculated the geometric mean for the three reference genes and used this value in Equation 1. To compare the transcript levels of the target gene across the different concentrations compared with the control level, the log 2 -difference in MNE (treated vs. control) was calculated and plotted, giving the log 2 fold change for each concentration at each time point studied (Equation 2).
RESULTS

Effect of VPA on Cell Number and Viability in P19 Embryonal Carcinoma Cells
No apparent adverse cellular effects were observed after 6 h VPA exposure (not shown). After 24 h of exposure (Fig. 1) , the total number of cells at all VPA concentrations tested (0.5-25mM) was higher than the number of cells (760,000 ± 50,000 SD) present at the start of exposure (Fig. 1A) , although at ! 1mM VPA the final number of cells was significantly (p < 0.05) lower than in the controls. At !2.5mM VPA, the final number of cells leveled off around 1.5 3 10 6 (Fig. 1A) , that is, at approximately twice the starting number, and there was a significantly (p < 0.01) decreased cell viability and increased cell death (Fig. 1A) , which was accompanied by an increase in cleaved caspase 3 (Fig. 1B) .
VPA-Induced Gene Expression Changes in P19 Embryonal
Carcinoma Cells
Total RNA extracted from P19 cells cultured in the absence or presence of 1, 2.5, or 10mM VPA for 1.5, 6, or 24 h was VALPROIC ACID-INDUCED GENE DEREGULATION subjected to replicated microarray analysis, using CodeLink UniSet I Mouse 20K Expression Bioarrays. After data normalization and filtering, expression values were obtained for 15,308 array elements (oligonucleotide probes) across all arrays. Using a linear model based on the average log 2 fold changes at 1 and 2.5mM VPA for each time point (see Materials and methods) and a moderated F-test (Smyth, 2004) , we found a significant VPA response at any of the time points for 7.7% (F-test p value < 10 À7 ) to 19.4% (F-test p value < 10 À3 ) of the probes in the filtered gene list (Fig. 2 ). There was a significant VPA response across all times points for 133 (F-test p value < 10 À7 ) to 421 (F-test p value < 10 À3 ) of these probes (Figs. 2A-E), corresponding to 11.2-14.2% of significant array elements. Estimating the overall VPA response as an average across all arrays per time point (M av ; see Materials and methods), an additional 776 probes were found to show a putative VPA response (giving a total of 3748 probes; Fig. 2F ), 599 of which had jM av j > 0.75 in at least one time point, and 309 had a consistent down (188 probes; M av < À0.5) or up (121 probes; M av > 0.5) response across two consecutive time points.
The highest percentage of probes (~70-75%) with a significant VPA-induced change was found at the 6-h time point ( Figs. 2A-E) . The corresponding percentage range was similar (~65-70%) at the 24-h time point, but considerably lower (~20-35%) at 1.5 h. PCA of the arrays revealed that the 6-h controls cluster together with the 1.5-h controls (as well as VPA-exposed) but not with the 24-h controls (Supplemental Fig. 1A ). However, PCA of control-subtracted arrays (Supplemental Fig. 1B) showed an overall increasing effect of VPA with longer exposure time and/or higher VPA concentration.
Among the numerous array elements showing signs of deregulated gene expression in response to VPA (Fig. 2) , we defined a core subset of nearly 200 VPA target genes whose 136 expression was downregulated (68 genes; Supplemental Table 2) or upregulated (125 genes; Supplemental Table 3 ) with high probability (F-test p value < 10 À7 ) after both 1.5 and 6 h VPA exposure, including 37 and 93 genes, respectively, that were also highly significant at the 24-h time point. The shape of the dose-response curves (Supplemental Fig. 2) for many of these genes indicates that their expression may not only be deregulated within 6 h of VPA exposure, but also at relatively low concentrations ( 1mM) of VPA. The dose-response curves (Supplemental Fig. 2 ) also illustrate that the log 2 fold changes for some of these genes were modest. GO analysis of the core subset of candidate genes revealed a significant (p < 0.05) overrepresentation of the biological process transcriptional regulation among the downregulated genes, and apoptosis among the upregulated genes (Table 1) .
VPA Response of Genes Related to Neural Tube Defects
Among the downregulated genes in the core subset of candidate VPA targets (Supplemental Table 2 ), two (Folr1 and Gtf2i) are known to be functionally related to NTD (Enkhmandakh et al., 2006; Piedrahita et al., 1999) . A total of 179 of the 15,308 array probes for which expression data were obtained represent genes known from genetic mouse models to be NTD-related, as compiled from the recent listings by Harris and Juriloff (2007) and Copp et al. (2003) , and AmiGO (http://amigo.geneontology.org/) using the GO biological process terms ''neural tube closure,'' (GO:0001843) ''anterior neuropore closure,'' (GO:0021506) and ''neural tube formation'' (GO:0001841). There were 61 NTD-related probes (34.1% of the 179 NTD-related probes), representing 59 genes ( Table 2) , among the 3748 probes defined above (Fig. 2F) as VPA responsive, and which constitute 24.5% of the whole set of 15,308 array probes. A significant VPA response at any time point was found for 17 (F-test p value < 10 À7 ) to 43 (F-test p value < 10 À3 ) NTD-related array probes (Table 2) , which corresponds to 9.5-24% of the filtered list of NTD-related probes. This percentage was comparable to that of the corresponding subset of significant probes in the whole set ) at 1.5 and 6 h (Supplemental Table 2 ). ) at 1.5 and 6 h (Supplemental Table 3 ).
VALPROIC ACID-INDUCED GENE DEREGULATION across a wide range of significance levels (Fig. 3A) . Moreover, the average effect of VPA on expression across the entire array for the 179 NTD-related probes was comparable to that of the whole set of 15,308 probes (Fig. 3B) . a Average log 2 fold change across all three concentrations, calculated as the average log 2 fold change of the VPA response (vs. controls) across all arrays used to measure samples from VPA-exposed cells (i.e., three for 1mM, two for 2.5mM, and one for 10mM, with added replicates for 1.5 h as noted in Material and methods).
b Statistical significance using a linear model based on the average log 2 fold changes at 1 and 2.5mM VPA for each time point (see Materials and methods) and a moderated F-test. 
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VPA Response of Putative HDAC Target Genes A core set of 13 genes has been reported to be commonly regulated by three different HDAC inhibitors (other than VPA) in three independent human tumor cell lines (Glaser et al., 2003) , and consistent deregulation downstream of HDAC inhibition has been reported for at least two more genes (Gsn and Txnip) in gene expression profiling studies (Butler et al., 2002; Glaser et al., 2003; Huang and Pardee, 2000) . There were signs of deregulated gene expression in response to VPA in P19 cells for most of these putative HDAC inhibition target genes (seven out of 10 probes for which data were obtained), all of which were regulated (up or down) as predicted (Table 3) .
A list of 168 putative Hdac1 target genes was generated through reanalysis of the publicly available data from a recent microarray study of ES cells derived from Hdac1 À/À and wildtype mice (Zupkovitz et al., 2006) . There was an apparent VPA response in P19 cells for 40% (60 of 145 probes for which data were obtained), two-thirds of which were regulated in the same direction as in the Hdac1 À/À ES cells: 31 upregulated (31.6% of 98 probes; Table 4 ) and 9 downregulated (19.1% of 47 probes; Table 5 ). Among the downregulated Hdac1 target genes (Table 5) were Lefty1 (Supplemental Table 2 ) and the NTD-related gene Gja1 (Table 2) .
The average effect of VPA on expression across the entire array was higher for all 155 HDAC-related array probes than for the whole set of 15,308 probes (Fig. 4A) , and showed increasing differences at higher VPA concentration and/or longer exposure time. Overall, 30.3% of the HDAC-related probes showed a VPA response in the direction (up or down) predicted by previous studies. A significant VPA response at any time point was found for 12.9% (F-test p value < 10 À7 ) to 31% (F-test p value < 10 À3 ) of the filtered list of HDACrelated probes (Fig. 4B ). This percentage was higher than for the corresponding subset of significant probes in the whole set across a wide range of significance levels (Fig. 4B ), but only when not taking into account the direction of change (up or down) predicted by previous studies (Fig. 4B) . Average log 2 fold change across all three concentrations, calculated as the average log 2 fold change of the VPA response (versus controls) across all arrays used to measure samples from VPA-exposed cells (i.e., three for 1mM, two for 2.5mM, and one for 10mM, with added replicates for 1.5 h as noted in ''Material and methods'').
b Statistical significance using a linear model based on the average log 2 fold changes at 1 and 2.5mM VPA for each time point (see ''Materials and methods'') and a moderated F-test. 
À3
a Average log 2 fold change across all three concentrations, calculated as the average log 2 fold change of the VPA response (vs. controls) across all arrays used to measure samples from VPA-exposed cells (i.e., three for 1mM, two for 2.5mM, and one for 10mM, with added replicates for 1.5 h as noted in ''Material and methods'').
b Statistical significance using a linear model based on the average log 2 fold changes at 1 and 2.5mM VPA for each time point (see ''Materials and methods'') and a moderated F-test.
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Confirmation of Candidate VPA Target Genes
The identity and transcriptional responsiveness to VPA was confirmed for all thirteen genes (Supplemental Table 1 ) selected for follow-up analysis using qPCR (Table 6 ). These genes showed an apparently similar concentration-and timedependent VPA-response pattern in both the microarray and qPCR data (Supplemental Fig. 3) .
A cross-platform comparison of genes selected in our previously published study (Kultima et al., 2004) was undertaken in order to extract further genes whose transcriptional responsiveness to VPA has been assessed using independent probe sequences (NIA clone set cDNAs vs. CodeLink DNA oligonucleotides) and samples. When NIA cDNA clones that in the previous microarray analysis showed a significant transcriptional response in P19 cells exposed to 1mM VPA for 24 h (Kultima et al., 2004, Supplemental Material, Tables 3 and 4 , available at http://www.ehponline. org/txg/members/2004/7034/supplemental.pdf) were now linked to and plotted against data obtained in the CodeLink Bioarrays for the corresponding genes, 54 of 104 linked clones (52%) showed a similar VPA response (log 2 fold change < À0.5 or > 0.5) in the CodeLink data for P19 cells exposed to 1mM VPA for 24 h (Fig. 5A) ; these candidate VPA target genes are listed in Supplemental Table 4 . Moreover, when NIA cDNA clones that showed a significant response in embryos collected 6 h after ip injection of 600 mg/kg bodyweight on gestational day 8 in the NMRI mouse (Kultima et al., 2004, Supplemental Material, Tables 1 and 2 , available at http://www.ehponline. org/txg/members/2004/7034/supplemental.pdf) were linked to and plotted against CodeLink data for the corresponding genes, 28 of 54 linked clones (52%) showed a similar response (log 2 fold change < À0.5 or > 0.5) in the CodeLink data for P19 cells exposed to 1mM VPA for 24 h (Fig. 5B) ; these candidate VPA target genes are listed in Supplemental Table 5 . In addition to being a large-scale approach toward confirming the identity and VPA responsiveness of potential candidate genes, these cross-platform comparisons indicated that the CodeLink Expression Bioarray system is more sensitive than the spotted cDNA arrays.
DISCUSSION
The utility of an in vitro system in the mechanistic characterization of a developmental toxicant was explored, using microarrays to detect genes susceptible to deregulation by the well-known teratogen VPA in the pluripotent embryoderived mouse embryonal carcinoma cell line P19. Such genes may not only provide molecular targets and markers of teratogen action that could contribute to improved in vitro Average log 2 fold change across all three concentrations, calculated as the average log 2 fold change of the VPA response (vs. controls) across all arrays used to measure samples from VPA-exposed cells (i.e., three for 1mM, two for 2.5mM, and one for 10mM, with added replicates for 1.5 h as noted in ''Material and methods''). Average log 2 fold change across all three concentrations, calculated as the average log 2 fold change of the VPA response (vs. controls) across all arrays used to measure samples from VPA-exposed cells (i.e., three for 1mM, two for 2.5mM, and one for 10mM, with added replicates for 1.5 h as noted in ''Material and Methods'').
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testing strategies, but also novel insights into the mechanisms by which drugs cause malformations.
VPA Produces Time-and Concentration-Related Effects in P19 Cells
P19 cells exposed to VPA were able to undergo cell division at all concentrations tested. That the final cell counts after 24 h leveled off around a number suggestive of one doubling (celldoubling rate~16 h) when the VPA concentration was above a certain threshold (in the range of 1-2.5mM) is in line with the antiproliferative effects of VPA due to cell cycle arrest in G 1 (Yeow et al., 2006) . Hence, the data are compatible with the cells being able to enter and complete mitosis if already past this critical point in the cell cycle when VPA exposure is initiated, and then to be arrested in G 1 of the next cell cycle if the VPA concentration is nonpermissive. No such threshold effect was evident for cell death, which increased gradually with increasing VPA concentrations (the apparent EC 50 for the endpoint cell death was approximately 6mM). The concomitant increase in activated caspase 3 implies that caspase 3-mediated apoptosis (Dragunow et al., 2006; Krämer et al., 2008) is involved in the concentration-dependent cell death induced by VPA in P19 cells. VPA-induced gene expression responses related to G 1 -S phase progression and apoptosis were identified in the microarray analysis (see below).
The basal gene expression profile of the 24-h controls deviated from the 1.5-h and 6-h controls, raising the possibility that changes in gene expression unrelated to exposure might occur during prolonged culture of P19 cells; the 1.5, 6, and 24-h time points were measured approximately 18.5, 23, and 41 h, respectively, after plating of the cells. Even if the toxicogenomic response at a given time point is not disturbed by such altered transcriptional states of the control cells, comparisons between early and late time points could potentially be confounded. The current data point toward 6 h being an ideal assay time in the P19 system; in addition to avoiding possible problems associated with any alterations in the control state, the 6-h time point resulted in the maximal number of VPA-responsive genes.
VPA Deregulates the Expression of a Large Number of Genes as a Primary Mechanism of Action
This study uncovered a multitude of genes whose expression could potentially be deregulated by VPA in embryonic cells, and thus expands the findings of previous microarray studies (Gurvich et al., 2005; Kultima et al., 2004; Massa et al., 2005; Okada et al., 2005) . A large fraction (about 40%) of the genes found to be up-or downregulated with a high probability (F-test p value < 10 À7 ) after 6 h showed evidence of having a significant (F-test p value < 10 À3 ) response in the same direction already after 1.5 h, and the shape of the dose-response curve for many genes indicated an apparently high sensitivity to VPA (low EC 50 ). In light of the apparent absence of adverse cellular effects after a short exposure time ( 6 h) and/or at a low VPA concentration ( 1mM) it appears unlikely that gene expression changes observed under these conditions would be secondary to general cytotoxicity. VPA-induced cytotoxicity may thus be the result of early changes in gene expression rather than the other way around. This raises the possibility that deregulation of gene expression is a major cause of VPA-induced teratogenicity. In other words, the disruptive effects of VPA on embryonic development could be a direct consequence of detrimental cellular events occurring downstream of the abnormal expression of critical genes. Chapin et al. (2007) suggested that any change in gene expression would represent an adverse effect on the embryo, FIG. 5 . Cross-platform comparison of microarray data. Log 2 fold changes determined in NIA clone set cDNA microarrays for array elements previously (Kultima et al., 2004) found to show significant transcriptional response to VPA in (A) P19 cells exposed to VPA for 1mM for 24 h, and (B) embryos collected 6 h after ip injection of 600 mg/kg bodyweight on gestational day 8 in the NMRI mouse, are plotted against log 2 fold changes determined in CodeLink Expression Bioarrays for P19 cells exposed to VPA for 1mM for 24 h.
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and that small changes in the expression of many genes could be summed to show the collective effect of an exposure. Thus, it remains an open question to which degree the fold changes detected for individual genes in P19 cells in vitro would need to be attained in target tissues in vivo for toxic pathways to be initiated. Furthermore, it is not straightforward to select which particular candidate genes to pursue as potential markers of VPA-induced teratogenicity.
A core subset of nearly 200 genes (Supplemental Tables 2  and 3) , arbitrarily defined based on their high probability of a VPA response within 6 h of exposure, encode proteins involved in apparently relevant biological functions, such as transcription, translation, signaling, various transport processes, cell cycle control, or apoptosis. The significantly enriched GO term among the downregulated genes was transcriptional regulation, and among the upregulated genes it was apoptosis (Table 1) . Whereas many genes of this core subset showed only limited fold changes, which might render them unsuitable for use in a testing system, many genes with high fold changes (e.g., Ddit3) did not meet the criteria to be included in this particular subset.
VPA Deregulates the Expression of Genes Related to Neural
Tube Defects To perform follow-up functional studies in vivo for the plethora of putative candidate genes discovered in vitro would be an impractical and inefficient way of assessing the potential relevance of the gene expression response in the in vitro system. As an alternative, we focused on the major toxicological outcome of VPA exposure during early embryogenesis, the induction of NTD, and asked to what extent genes known to be crucial for neural tube development were deregulated by VPA in P19 cells. Almost 200 functionally diverse genes have been associated with NTD phenotypes in the mouse (Copp et al., 2003; Harris and Juriloff, 2007) . In total, 59 NTD-related genes showed evidence of altered mRNA levels in P19 cells after VPA exposure. Given that the mutation, knockout, or overexpression in the mouse embryo of any one (or occasionally two) of these genes is sufficient to induce NTD, the current finding that perhaps more than a quarter of the genes known to have critical functions in neural tube formation and closure may inherently be sensitive to transcriptional deregulation by VPA is intriguing. Whether or not the combined disturbed expression of several genes critically involved in neural tube development is the mechanism by which VPA specifically induces NTD in vivo, the present study revealed some attractive VPA target genes that may contribute to such an effect.
Reduced Expression of Genes Associated with NTD as a Deficiency Phenotype
Two of the NTD-related genes, Folr1 and Gtf2i, were found in the core subset of downregulated VPA target genes (Table 2) , and in view of this emerge as prime candidates to explore as mechanistically relevant markers of VPA teratogenesis. Incomplete expression of the Folr1 gene, which encodes the folate receptor 1 (also known as folate-binding protein 1, Folbp1), is sufficient to produce NTD in the mouse embryo, as indicated by the Folr1 À/À phenotype (Piedrahita et al., 1999) and the outcome of Folr1-antisense experiments (Hansen et al., 2003) . Folr1 has a major role in the uptake of folate into cells, and a reduced capacity of folate uptake receptors in the neural folds of Folr1-deficient embryos can be countered by increasing the concentration of the ligand (Hansen et al., 2003; Piedrahita et al., 1999; Spiegelstein et al., 2004) . The association between maternal folate deficiency and increased risk of NTD in humans, as well as maternal dietary folate supplementation and reduced incidence of NTD in high-risk groups, is well established (Beaudin and Stover, 2007; Greene and Copp, 2005) . Moreover, folate has been reported to protect against VPA-induced NTD in mice (Dawson et al., 2006; Elmazar et al., 1992; Padmanabhan and Shafiullah, 2003; Trotz et al., 1987; Tung and Winn, 2008; Wegner and Nau, 1991) . Given the expression of Folr1 in the neural folds (Saitsu et al., 2003) and the accumulation of VPA in the neuroepithelium of the mouse embryo (Dencker et al., 1990) , the finding that Folr1 expression is susceptible to downregulation by VPA in exposed cells provides a possible mechanism by which impaired folate metabolism could contribute to NTD in VPAexposed embryos in vivo. Downregulation of Folr1 would also explain why Folr2 À/À embryos, which develop normally (Piedrahita et al., 1999) , have an increased frequency of NTD when exposed to VPA (Spiegelstein et al., 2003) . Folr2-deficient embryos may normally be rescued by the expression of Folr1, which binds folate with a higher affinity than Folr2 (Brigle et al., 1994) , but not vice versa. Hence, reduced Folr1 expression in the absence of Folr2 could contribute to inadequate folate transport.
Similar mechanistic arguments could be made for Gtf2i and several other downregulated genes whose deficiency phenotype comprises NTD (e.g., Arnt, Axin1, Crebbp, Cyp26a1, Deaf1, Hif1a, Lmo4, Lrp6, Marcksl1, Rab23, Sall1, Sall4, Sirt1, and Vangl2). In support of the notion that concurrent downregulation of several essential genes could produce compounded effects, the majority of these genes encode proteins that directly (at the level of DNA) or indirectly (signaling pathways) influence transcriptional regulation, and which in several cases act together (e.g., Arnt and Hif1a, Deaf1, and Lmo4, Sall1, and Sall4) or in the same pathway (e.g., Axin1and Lrp6, Cyp26a1, and Aldh1a2), or whose activities converge on the same processes, such as the regulation of G 1 -S progression (e.g., Gtf2i, Sall4, Crebp).
Transcription:
Gtf2i encodes the multifunctional transcription factor TFII-I, whose activity is regulated by extracellular growth VALPROIC ACID-INDUCED GENE DEREGULATION factors as well as binding to Hdac3 (Wen et al., 2003) . Because TFII-I has been shown to promote G 1 -S progression through transcriptional activation of the cyclin D1 gene (Ccnd1) (Desgranges et al., 2005) , one of several cyclin genes that were downregulated by VPA in P19 cells (see further below), the downregulation of Gtf2i is in accord with the G 1 -phase cell cycle arrest induced by VPA (see above).
Sall1 and Sall4 encode multi-zinc-finger transcriptional repressors that cooperate with each other (Sakaki-Yumoto et al., 2006) , and at least Sall1 is known to recruit HDACs in the nucleosome remodeling and deacetylase corepressor complex (Kiefer et al., 2002; Lauberth and Rauchman, 2006) . Interestingly, Sall4 À/À ES cells and ES cells subjected to siRNA knockdown of Sall4 expression have impaired proliferation, which has been attributed to inefficient G 1 -S phase progression (Sakaki-Yumoto et al., 2006) .
Deaf1 and Lmo4 encode zinc-finger transcriptional regulators that directly interact with each other, and whose knockout phenotypes are largely overlapping (Hahm et al., 2004) .
Arnt encodes the aryl hydrocarbon receptor (Ahr) nuclear translocator protein, which forms a heterodimeric transcription factor complex together with hypoxia-inducible factors such as Hif-1a, encoded by Hif1a, and the dioxin-receptor Ahr.
Histone acetylation:
Crebbp encodes the transcriptional coactivator and integrator CREB-binding protein (CBP), a zinc-finger protein with histone acetylase activity (Chan and La Thangue, 2001) that is known to interact with cyclin D1 as well as a wide variety of transcriptional regulators and other proteins (Kasper et al., 2006) .
Sirt1 encodes a nicotinamide adenine dinucleotidedependent HDAC, which in addition to histones also interacts with nonhistone proteins. Deacetylation of the transcription factor p53 (whose knockout phenotype also comprises NTD) leads to inhibition of p53-dependent apoptosis (Cheng et al., 2003) . The expression of the Sirt1 gene has been shown to be downregulated in the head of mouse embryos exposed to VPA in utero (Okada et al., 2005) .
Sonic hedgehog (Shh) and Wnt-signaling pathways:
Rab23 encodes a member of the Rab family of vesicletransport GTPases known to negatively regulate the Shh signaling pathway (Eggenschwiler et al., 2001 (Eggenschwiler et al., , 2006 , the excessive signaling of which has been associated with NTD (Copp et al., 2003; Ybot-Gonzalez et al., 2007) .
The planar cell polarity gene Vangl2 encodes the Drosophila van Gogh/strabismus homolog of the loop-tail (Lp) mutant (Kibar et al., 2001) , a component of the noncanonical Wnt-signaling pathway.
Axin1, the gene of the Fused locus (Zeng et al., 1997) , encodes a negative regulator of the canonical Wnt-signaling pathway, and Lrp6, the gene mutated in the folate-responsive crooked-tail (Cd) mouse (Carter et al., 2005) , encodes a Wnt coreceptor. That both Lrp6 deficiency and hyperactivity has been associated with NTD (Carter et al., 2005) is interesting in the light of the VPA-induced upregulation in P19 cells of Wnt3a, another Wnt gene whose knockout phenotype comprises NTD.
Retinoic acid (RA) signaling pathway:
Cyp26a1 encodes a cytochrome P450 enzyme with RAdegrading activity that is important for the spatial restriction of RA signaling during embryogenesis, and Cyp26a1 À/À embryos show similar defects as wild-type embryos exposed to excessive RA (Abu-Abed et al., 2001; Sakai et al., 2001) . The embryonic expression pattern of Cyp26a1 essentially is mutually exclusive to that of Aldh1a2, the gene encoding the major RA-synthesizing enzyme, and the developmental defects induced by Cyp26a1 deficiency are rescued by reduced expression of Aldh1a2 (Niederreither et al., 2002) . Given that Cyp26a1 was downregulated and Aldh1a2 was found to be upregulated by VPA in P19 cells, it is tempting to speculate that ectopic RA signaling could contribute to VPA teratogenesis.
RA is known to repress the expression of Otx2 , a homeobox gene whose head-specific expression (Simeone et al., 1992) is essential for head development . In this study we found downregulation of Otx2, as well as its downstream target gene Fgf15 (Zakin et al., 2000) , in response to VPA.
Increased Expression of Genes Associated with NTD as an Overexpression Phenotype
Some of the few genes whose overexpression in mice results in NTD (Copp et al., 2003) were upregulated by VPA in P19 cells, for example, Klf5, which encodes a zinc-finger transcription factor (Sur et al., 2006) , and Msx2, which encodes a homeodomain transcription factor (Winograd et al., 1997) .
VPA Deregulates the Expression of HDAC Target Genes
Several putative HDAC target genes were found to be deregulated by VPA in P19 cells. However, the percentage of these genes changing in the same direction (up or down) predicted by previous data (Butler et al., 2002; Glaser et al., 2003; Huang and Pardee, 2000; Zupkovitz et al., 2006) was not higher than for the general background of VPA-responsive genes. Moreover, among the large number of significant genes with an early (1.5 h) VPA response ( Fig. 2 ; Supplemental Tables 2 and 3) , only a few known or putative HDAC target genes (e.g., Ddx19b, Gabarapl2, Lefty1, Stmn2) were found (Tables 3-5 ). This indicates that HDAC inhibition might not be the predominant driver of early gene expression changes induced by VPA in P19 cells. This is an interesting finding given that HDAC inhibition has been suggested to be an important mechanism by which VPA deregulates gene 144 expression (Göttlicher et al., 2001; Phiel et al., 2001; Reid et al., 2005) and induces NTDs (Eikel et al., 2006; Gurvich et al., 2005) and other birth defects . HDAC inhibition by VPA was previously inferred to occur in mouse embryos (Eikel et al., 2006; Kultima et al., 2004; Menegola et al., 2005) as well as in P19 cells (Kultima et al., 2004) . However, the role of HDAC inhibition in teratogenesis has recently been questioned (Wise et al., 2007) . If VPA teratogenicity involves abnormal expression of multiple genes, as might be inferred from our findings, the current data are compatible with some but not all of those genes being deregulated downstream of HDAC inhibition.
Two apparent developmentally important HDAC target genes were deregulated by VPA: Lefty1 (downregulated) encodes an antagonist of the TGF-b superfamily member nodal, which inhibits G 1 -S cell cycle progression by downregulating cyclin D1 expression (see above) and induces apoptosis (Munir et al., 2004) . In the zebrafish, nodal is required for anterior neural tube closure (Aquilina-Beck et al., 2007) , whereas in the mouse it has not been classified as an NTD-related gene because null mutants die around gastrulation.
Bmp4 (upregulated) encodes the TGFb superfamily member bone morphogenetic protein (Bmp)-4, the increased activity of which, in embryos deficient for the Bmp antagonist noggin, has been related to open neural tube (Stottmann et al., 2006) . Bmp4 is similar to Bmp2, the activity of which must be antagonized (by noggin) for proper bending of the neural plate to occur during neurulation (Ybot-Gonzalez et al., 2007) .
VPA Deregulates Many Genes Encoding Zinc-Binding Proteins
Many of the genes found to be downregulated by VPA in this study encode zinc-finger transcription factors (several examples are given above), that is, proteins whose activities are dependent on adequate Zn 2þ availability. The expression of both Mt1 and Mt2, which encode the zinc-sequestering proteins metallothionein-1 and -2, respectively, was previously reported to be induced by VPA (Kultima et al., 2004) , in favor of the hypothesis that reduced levels of available Zn 2þ may contribute to NTD (Zimmerman, 1984) . Although the induction of Mt2 (after 24 h) was confirmed in this study, Mt1 was not represented in the CodeLink Bioarray used. Both of these genes are putative HDAC target genes, even if only Mt1 was among the genes reported to be upregulated both by HDAC inhibition (Glaser et al., 2003) and the absence of Hdac1 (Zupkovitz et al 2006) .
Other Genes
Further studies are needed to determine which individual genes of the large number of putative VPA targets, besides the known NTD-related genes (see above), warrant to be explored as functionally relevant markers of VPA teratogenicity. Some attractive candidates in addition to those (Otx2, Fgf15, Lefty1) already discussed above:
Ccnl1, which encodes cyclin L1, was downregulated by VPA in P19 cells, along with the closely related gene Ccnl2 (Table 2 ). Ccnl1 has previously been shown to be downregulated in the head of mouse embryos exposed to VPA in utero (Okada et al., 2005) .
Gdf3, like Lefty1 (and Lefty2, which was not represented in the CodeLink Bioarray), is a ''stemness'' gene (Smith, 2001) of the TGFb superfamily that is expressed in pluripotent ES cells, and whose expression in P19 cells was downregulated by VPA. Gdf3 functions as a BMP inhibitor to regulate pluripotency (Levine and Brivanlou, 2006) .
Ddit3 encodes the C/EBP transcription factor family member DNA-damage inducible transcript 3 (also known as Gadd153 and CHOP-10), which functions as a dominant negative regulator of transcription and an inducer of apoptosis (Wang et al., 1998) . This gene showed a robust time-and concentration-dependent increase in expression and a very high fold-induction (up to 100-fold after 24 h at 10mM VPA), and this response could tentatively be used to gauge VPA exposure.
Conclusion
This study in P19 cells not only shows that VPA may have an inherent ability to deregulate the expression of a multitude of genes, but also that many of the genes that are known to have critical functions in neural tube formation and closure may be potential VPA targets. It remains to be determined if the combined disturbed expression (Chapin et al., 2007) of several such NTD-related genes may contribute to VPAinduced NTD in vivo. The deregulation of many developmentally important genes in a simple monolayer cell system in which the morphogenetic processes that are disturbed by VPA in the embryo do not and cannot actively occur indicates that the ability to deregulate gene expression may be a primary teratogenic mechanism of VPA. Further studies are needed to determine which of the several genes that show an early VPA response and/or a response at a low VPA concentration may be primary VPA targets. Moreover, it remains to be elucidated to what extent HDAC inhibition contributes to the deregulation of such genes and to VPA teratogenicity.
These data are promising in terms of the prospect of using in vitro models in conjunction with gene expression profiling in order to find gene expression changes that may be explored as potential markers of toxicity, including teratogenicity, and that could be utilized when designing in vitro screening tests for developmental toxicity. 
